Pictet Asset Management (Switzerland)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$270K	Sell	2,646 -558	-17%	-$52.8K	﹤0.01%	1565
2023 Q1	$291K	Buy	+3,204	New	+$188K	﹤0.01%	1505
2021 Q4	–	Sell	-98,616	Closed	-$9.92M	–	1822
2021 Q3	$9.92M	Buy	+98,616	New	+$11.6M	0.01%	666

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RETA Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 17% in Q2 2023, selling an estimated $52.8K and leaving 2,646 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #1565.

Pictet Asset Management (Switzerland) first reported a position in RETA in Q3 2021 and has held it in 3 quarters since. The position peaked at $9.92M in Q3 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Pictet Asset Management (Switzerland) held 2,646 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $270K as of Q2 2023.
Pictet Asset Management (Switzerland) sold 558 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $52.8K.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1565 holding.
Pictet Asset Management (Switzerland) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2021 and has held it in 3 quarters since.
Pictet Asset Management (Switzerland)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.92M in Q3 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.